EE05344B1 - Ühendi (deaminohüdroksü)toremifeeni kasutamine tupekuivuse v?i seksuaaldüsfunktsiooni ravis menopausi ajal v?i järel - Google Patents

Ühendi (deaminohüdroksü)toremifeeni kasutamine tupekuivuse v?i seksuaaldüsfunktsiooni ravis menopausi ajal v?i järel

Info

Publication number
EE05344B1
EE05344B1 EEP200300031A EEP200300031A EE05344B1 EE 05344 B1 EE05344 B1 EE 05344B1 EE P200300031 A EEP200300031 A EE P200300031A EE P200300031 A EEP200300031 A EE P200300031A EE 05344 B1 EE05344 B1 EE 05344B1
Authority
EE
Estonia
Prior art keywords
compound
treatment
deaminohydroxy
menopause
toremifene
Prior art date
Application number
EEP200300031A
Other languages
English (en)
Estonian (et)
Inventor
Halonen Kaija
Kangas Lauri
W. Degregorio Michael
Original Assignee
Hormos Medical Corporation
Tess Diagnostics And Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24504996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05344(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Corporation, Tess Diagnostics And Pharmaceuticals, Inc. filed Critical Hormos Medical Corporation
Publication of EE200300031A publication Critical patent/EE200300031A/xx
Publication of EE05344B1 publication Critical patent/EE05344B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200300031A 2000-07-21 2001-05-02 Ühendi (deaminohüdroksü)toremifeeni kasutamine tupekuivuse v?i seksuaaldüsfunktsiooni ravis menopausi ajal v?i järel EE05344B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/625,199 US6245819B1 (en) 2000-07-21 2000-07-21 Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
PCT/FI2001/000414 WO2002007718A1 (fr) 2000-07-21 2001-05-02 Procede de traitement de troubles climateriques chez les femmes durant ou apres la menopause

Publications (2)

Publication Number Publication Date
EE200300031A EE200300031A (et) 2004-10-15
EE05344B1 true EE05344B1 (et) 2010-10-15

Family

ID=24504996

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300031A EE05344B1 (et) 2000-07-21 2001-05-02 Ühendi (deaminohüdroksü)toremifeeni kasutamine tupekuivuse v?i seksuaaldüsfunktsiooni ravis menopausi ajal v?i järel

Country Status (31)

Country Link
US (5) US6245819B1 (fr)
EP (1) EP1305014B1 (fr)
JP (2) JP5575351B2 (fr)
KR (1) KR100880564B1 (fr)
CN (1) CN1287775C (fr)
AT (1) ATE300289T1 (fr)
AU (2) AU2001258449B2 (fr)
BG (1) BG65943B1 (fr)
BR (1) BR0112659A (fr)
CA (1) CA2416480C (fr)
CY (1) CY1105370T1 (fr)
CZ (1) CZ299439B6 (fr)
DE (1) DE60112301T2 (fr)
DK (1) DK1305014T3 (fr)
EE (1) EE05344B1 (fr)
ES (1) ES2241819T3 (fr)
HK (1) HK1056694A1 (fr)
HR (1) HRP20030024A2 (fr)
HU (1) HU229361B1 (fr)
IL (1) IL153823A (fr)
MX (1) MXPA03000378A (fr)
NO (1) NO329954B1 (fr)
NZ (1) NZ524181A (fr)
PL (1) PL202654B1 (fr)
PT (1) PT1305014E (fr)
RU (1) RU2268035C2 (fr)
SI (1) SI1305014T1 (fr)
SK (1) SK287096B6 (fr)
UA (1) UA74386C2 (fr)
WO (1) WO2002007718A1 (fr)
ZA (1) ZA200300342B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
CA2408399A1 (fr) 2000-05-09 2001-11-15 Nitromed, Inc. Thermographie infrarouge et procede d'utilisation d'applications associees
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
CN100448437C (zh) * 2002-06-06 2009-01-07 霍尔莫斯医疗有限公司 抑制女性萎缩或治疗或预防与女性萎缩相关的症状的方法
WO2004037804A1 (fr) * 2002-10-22 2004-05-06 Oscotec Inc. Derives du furane pour la prevention et le traitement de l'osteoporose, et compositions pharmaceutiques contenant ces derives
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) * 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
ES2391626T3 (es) 2004-05-04 2012-11-28 Hormos Medical Ltd. Nuevas composiciones orales de ospemifeno
KR100734942B1 (ko) 2007-01-02 2007-07-03 김재현 여성 갱년기 증후군에 유효한 건강기능식품 조성물
ES2590262T3 (es) 2007-02-14 2016-11-21 Hormos Medical Ltd. Método para la preparación de derivados de trifenilbuteno con valor terapéutico
WO2008099060A2 (fr) * 2007-02-14 2008-08-21 Hormos Medical Ltd Procédés de préparation de fispémifène à partir d'ospémifène
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
RU2535112C2 (ru) * 2012-09-19 2014-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия министерства здравоохранения и социального развития" Способ лечения климактерических и урогенитальных расстройств у женщин в постменопаузе на фоне гипотириоза
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
AU2016229086B2 (en) 2015-03-10 2018-12-06 Shionogi Inc. Solid dispersions
US9750716B2 (en) 2015-03-19 2017-09-05 Wendy Anne Epstein Compounds and forms of treatment for female sexual disorders
RU2636619C1 (ru) * 2017-02-20 2017-11-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения вагинальной атрофии у женщин в постменопаузе с учетом состояния эпителия и микробиоценоза влагалища

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352699A (en) * 1992-04-30 1994-10-04 University Of Massachusetts Medical Center Use of retinioc acid to treat vaginal atrophy
US5461064A (en) 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5747059A (en) * 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
MXPA02007165A (es) 2000-01-28 2003-09-22 Endorech Inc Moduladores del receptor selectivo de estrogenos en combinacion con estrogenos.
US20010034340A1 (en) 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause

Also Published As

Publication number Publication date
NO20030273D0 (no) 2003-01-20
JP2004504345A (ja) 2004-02-12
US20100280131A1 (en) 2010-11-04
NO329954B1 (no) 2011-01-31
DK1305014T3 (da) 2005-08-22
CA2416480C (fr) 2009-12-08
BG107472A (bg) 2003-11-28
WO2002007718A1 (fr) 2002-01-31
EP1305014B1 (fr) 2005-07-27
NZ524181A (en) 2003-07-25
DE60112301T2 (de) 2006-05-24
JP5629746B2 (ja) 2014-11-26
JP5575351B2 (ja) 2014-08-20
KR100880564B1 (ko) 2009-01-30
IL153823A0 (en) 2003-07-31
AU2001258449B2 (en) 2004-07-29
CZ200326A3 (cs) 2003-05-14
CA2416480A1 (fr) 2002-01-31
RU2268035C2 (ru) 2006-01-20
MXPA03000378A (es) 2003-09-22
PL202654B1 (pl) 2009-07-31
US20140142195A1 (en) 2014-05-22
EP1305014A1 (fr) 2003-05-02
DE60112301D1 (de) 2005-09-01
HUP0301791A2 (hu) 2003-12-29
IL153823A (en) 2008-03-20
WO2002007718A8 (fr) 2002-11-14
SK16072002A3 (sk) 2003-06-03
JP2013060445A (ja) 2013-04-04
US6984665B2 (en) 2006-01-10
UA74386C2 (uk) 2005-12-15
SI1305014T1 (sl) 2005-12-31
HRP20030024A2 (en) 2006-12-31
BG65943B1 (bg) 2010-06-30
SK287096B6 (sk) 2009-12-07
KR20030048378A (ko) 2003-06-19
PL359506A1 (en) 2004-08-23
US6245819B1 (en) 2001-06-12
HK1056694A1 (en) 2004-02-27
CN1446085A (zh) 2003-10-01
AU5844901A (en) 2002-02-05
CN1287775C (zh) 2006-12-06
ZA200300342B (en) 2004-02-13
US20030036566A1 (en) 2003-02-20
NO20030273L (no) 2003-01-20
CY1105370T1 (el) 2010-04-28
BR0112659A (pt) 2003-06-24
PT1305014E (pt) 2005-09-30
HU229361B1 (en) 2013-11-28
US9566252B2 (en) 2017-02-14
HUP0301791A3 (en) 2008-01-28
US20050272825A1 (en) 2005-12-08
ATE300289T1 (de) 2005-08-15
CZ299439B6 (cs) 2008-07-30
ES2241819T3 (es) 2005-11-01
EE200300031A (et) 2004-10-15

Similar Documents

Publication Publication Date Title
EE05344B1 (et) Ühendi (deaminohüdroksü)toremifeeni kasutamine tupekuivuse v?i seksuaaldüsfunktsiooni ravis menopausi ajal v?i järel
RU2003105159A (ru) Способ лечения климактерических расстройств у женщин во время или после менопаузы
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
EA200201000A1 (ru) Гормон-заместительная терапия
TNSN07147A1 (fr) Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
LU92204I2 (fr) Dapoxetine sous toutes ses formes protégées par lebrevet de base
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
CY1105787T1 (el) Θepαπευτικη αντιμετωπιση η προληψη της ατροφιας του ουροποιογεννητικου συστηματος και τα συμπτωματα της σε γυναικες
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
DE60004996D1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
AU3737901A (en) Use of pde v inhibitors
AU2002211217A1 (en) Method of treating stroke
MXPA02007454A (es) Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231